2. Cho KS. Tuberculosis control in the Republic of Korea. Health Soc Welf Rev 2017;37:179-212.
4. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent
Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127-2135.
5. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. Nat Rev Dis Primers 2016;2:16076.
7. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 3rd ed. Cheongju: Korea Centers for Disease Control and Prevention; 2017.
8. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-755.
9. Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet 2016;387:1211-1226.
11. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol 2008;191:834-844.
12. Nachiappan AC, Rahbar K, Shi X, Guy ES, Mortani Barbosa EJ Jr, Shroff GS, Ocazionez D, Schlesinger AE, Katz SI, Hammer MM. Pulmonary tuberculosis: role of radiology in diagnosis and management. Radiographics 2017;37:52-72.
13. Jeong YJ, Lee KS, Yim JJ. The diagnosis of pulmonary tuberculosis: a Korean perspective. Precis Future Med 2017;1:77-87.
14. Shen GH, Tsao TC, Kao SJ, Lee JJ, Chen YH, Hsieh WC, Hsu GJ, Hsu YT, Huang CT, Lau YJ, Tsao SM, Hsueh PR. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in
Mycobacterium tuberculosis? Controversies and solutions Int J Antimicrob Agents 2012;39:201-205.
15. Gafoor K, Patel S, Girvin F, Gupta N, Naidich D, Machnicki S, Brown KK, Mehta A, Husta B, Ryu JH, Sarosi GA, Franquet T, Verschakelen J, Johkoh T, Travis W, Raoof S. Cavitary lung diseases: a clinical-radiologic algorithmic approach. Chest 2018;153:1443-1465.
16. Ketai L, Currie BJ, Holt MR, Chan ED. Radiology of chronic cavitary infections. J Thorac Imaging 2018;33:334-343.
19. Jhun BW, Jeon K, Eom JS, Lee JH, Suh GY, Kwon OJ, Koh WJ. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol 2013;51:811-817.
22. Lee KS, Hwang JW, Chung MP, Kim H, Kwon OJ. Utility of CT in the evaluation of pulmonary tuberculosis in patients without AIDS. Chest 1996;110:977-984.
23. Korea Centers for Disease Control and Prevention. Korea National Institute of Health. Korean Society of Clinical Micorbiology. Manual of laboratory tests for tuberculosis [Internet] Cheongju: Korea Centers for Disease Control and Prevention. 2013;cited 2018 Dec 18. Available from:
https://www.gidcc.or.kr/wp-content/uploads/2016/12/2013년-결핵검사지침.pdf
24. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence. Lancet Infect Dis 2003;3:288-296.
25. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, Small PM. Transmission of
Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-449.
26. Mixides G, Shende V, Teeter LD, Awe R, Musser JM, Graviss EA. Number of negative acid-fast smears needed to adequately assess infectivity of patients with pulmonary tuberculosis. Chest 2005;128:108-115.
27. Mase SR, Ramsay A, Ng V, Henry M, Hopewell PC, Cunningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007;11:485-495.
28. Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013;13:147-154.
32. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K. ATS Mycobacterial Diseases Subcommittee. American Thoracic Society. Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
33. Forbes BA, Hall GS, Miller MB, Novak SM, Rowlinson MC, Salfinger M, Somoskovi A, Warshauer DM, Wilson ML. Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin Microbiol Rev 2018;01. 31. [Epub]. 10.1128/CMR.00038-17.
37. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;1):CD009593.
38. Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Xpert(R) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 2018;8:CD012768.
39. Lee HS, Kee SJ, Shin JH, Kwon YS, Chun S, Lee JH, Won EJ, Choi HJ, Kim SH, Shin MG, Shin JH, Suh SP. Xpert MTB/RIF assay as a substitute for smear microscopy in an intermediate burden setting. Am J Respir Crit Care Med 2018;09. 25:[Epub]. 10.1164/rccm.201804-0654OC.
40. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, Gilpin C, de Dieu Iragena J, Falzon D, Raviglione M. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013;42:252-271.
41. Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM. study team. Xpert MTB/RIF Ultra for detection of
Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018;18:76-84.
42. Arend SM, van Soolingen D. Performance of Xpert MTB/RIF Ultra: a matter of dead or alive. Lancet Infect Dis 2018;18:8-10.
43. Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR. ASTRO-CM Trial Team. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 2018;18:68-75.
47. Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC. A standardised method for interpreting the association between mutations and phenotypic drug resistance in
Mycobacterium tuberculosis. Eur Respir J 2017;50:1701354.
48. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType(R) MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev 2016;9:CD010705.